ANNA MANDALAKAS to Anti-HIV Agents
This is a "connection" page, showing publications ANNA MANDALAKAS has written about Anti-HIV Agents.
Connection Strength
1.273
-
Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis. Clin Infect Dis. 2023 01 06; 76(1):10-17.
Score: 0.623
-
Predicting mortality within 1 year of ART initiation in children and adolescents living with HIV in sub-Saharan Africa: a retrospective observational cohort study. Lancet Glob Health. 2024 Jun; 12(6):e929-e937.
Score: 0.172
-
Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents. Clin Infect Dis. 2021 08 02; 73(3):e580-e586.
Score: 0.141
-
HIV-associated pediatric tuberculosis: prevention, diagnosis and treatment. Curr Opin HIV AIDS. 2018 11; 13(6):501-506.
Score: 0.117
-
Tuberculosis Treatment Outcomes Among HIV/TB-Coinfected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network. J Acquir Immune Defic Syndr. 2017 Jun 01; 75(2):156-163.
Score: 0.106
-
Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. J Pediatric Infect Dis Soc. 2015 Mar; 4(1):30-8.
Score: 0.085
-
Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low- and middle-income countries: a multicohort study. J Int AIDS Soc. 2019 09; 22(9):e25392.
Score: 0.031